Pontifícia Universidade Católica de Minas Gerais - PUC, Department of Dentistry, Belo Horizonte, MG, Brazil.
Universidade Federal de Minas Gerais - UFMG, School of Dentistry, Department of Restorative Dentistry, Belo Horizonte, MG, Brazil.
Braz Oral Res. 2022 Jul 11;36:e090. doi: 10.1590/1807-3107bor-2022.vol36.0090. eCollection 2022.
The topical glucocorticoid budesonide has been prescribed before and after sinus lift surgery as adjuvant drug treatment for maxillary sinus membrane inflammation. However, there is no study on the effects of budesonide on the regenerative process of bone grafting biomaterials. We investigated the effect of the association of budesonide with some biomaterials on the growth and differentiation capacity of pre-osteoblastic cells (MC3T3-E1 subclone 4). Xenogeneic (Bio-Oss and Bio-Gen) and synthetic hydroxyapatites (Osteogen, Bonesynth, and HAP-91) were tested in conditioned medium (1% w/v). The conditioned medium was then supplemented with budesonide (0.5% v/v). Cell viability was assessed using the MTT assay (48, 96, and 144 h), and mineralized nodules were quantified after 14 days of culture using the Alizarin Red Staining. Alkaline phosphatase activity was assessed through the release of thymolphthalein at day seven. All biomaterials showed little or no cytotoxicity. The Bio-Gen allowed significantly less growth than the control group regardless of the experimental time. Regarding differentiation potential of MC3T3-E1, the HAP-91-conditioned medium showed remarkable osteoinductive properties. In osteodifferentiation, the addition of budesonide favored the formation of mineral nodules when cells were cultured in medium conditioned with synthetic materials, whereas it weakened the mineralization potential of cells cultured in xenogeneic medium. Regardless of whether budesonide was added or not, Osteogen and Bio-Oss showed higher alkaline phosphatase activity than the other groups. Budesonide may improve bone formation when associated with synthetic biomaterials. Conversely, the presence of this glucocorticoid weakens the mineralization potential of pre-osteoblastic cells cultured with xenogeneic hydroxyapatites.
局部糖皮质激素布地奈德已被用于鼻窦提升手术后，作为上颌窦膜炎症的辅助药物治疗。然而，目前还没有研究布地奈德对骨移植生物材料再生过程的影响。我们研究了布地奈德与一些生物材料联合使用对前成骨细胞（MC3T3-E1 亚克隆 4）生长和分化能力的影响。我们在条件培养基（1%w/v）中测试了异种（Bio-Oss 和 Bio-Gen）和合成羟基磷灰石（Osteogen、Bonesynth 和 HAP-91）。然后在条件培养基中添加布地奈德（0.5%v/v）。通过 MTT 测定（48、96 和 144 h）评估细胞活力，并在培养 14 天后通过茜素红染色定量矿化结节。通过第 7 天释放百里酚酞来评估碱性磷酸酶活性。所有生物材料均显示出较小或无细胞毒性。无论实验时间如何，Bio-Gen 允许的生长都明显少于对照组。关于 MC3T3-E1 的分化潜力，HAP-91 条件培养基显示出显著的成骨诱导特性。在成骨分化中，当细胞在合成材料的条件培养基中培养时，添加布地奈德有利于矿化结节的形成，而当细胞在异种培养基中培养时，布地奈德削弱了矿化潜力。无论是否添加布地奈德，Osteogen 和 Bio-Oss 显示出比其他组更高的碱性磷酸酶活性。当与合成生物材料联合使用时，布地奈德可能会改善骨形成。相反，这种糖皮质激素的存在会削弱与异种羟基磷灰石培养的前成骨细胞的矿化潜力。
